Cargando…

The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis

PURPOSE: To discuss the role of benzydamine in the prevention and treatment of radiation-induced oral mucositis (OM) in head and neck (H&N) cancer patients. This document represents an expert opinion paper on indications and key-role aspects in OM pathogenesis, prevention and treatment. ORAL MUC...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolatou-Galitis, Ourania, Bossi, Paolo, Orlandi, Ester, René-Jean Bensadoun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410701/
https://www.ncbi.nlm.nih.gov/pubmed/33649918
http://dx.doi.org/10.1007/s00520-021-06048-5
_version_ 1783747155687636992
author Nicolatou-Galitis, Ourania
Bossi, Paolo
Orlandi, Ester
René-Jean Bensadoun
author_facet Nicolatou-Galitis, Ourania
Bossi, Paolo
Orlandi, Ester
René-Jean Bensadoun
author_sort Nicolatou-Galitis, Ourania
collection PubMed
description PURPOSE: To discuss the role of benzydamine in the prevention and treatment of radiation-induced oral mucositis (OM) in head and neck (H&N) cancer patients. This document represents an expert opinion paper on indications and key-role aspects in OM pathogenesis, prevention and treatment. ORAL MUCOSITIS: OM represents a common side effect of chemotherapy (CHT) and radiotherapy (RT). It consists in a painful erythema involving the oral cavity mucosa, which may progress to ulceration. Five biologically dynamic phases are considered crucial in mucositis: “initiation, signalling, amplification, ulceration and healing”. Oral environment and microbiota are fundamental in mucositis development being involved in susceptibility to infections and in ulceration consequences. Different agents against mucositis have been studied and the use of benzydamine is strongly supported in literature. The Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO) guidelines recommend its use for the prevention of OM in H&N patients undergoing RT and RT/CHT. BENZYDAMINE: Benzydamine is a local anti-inflammatory drug with analgesic properties. It can decrease TNF-α, IL-1β and prostaglandin synthesis, also inhibiting leukocyte-endothelial interactions, neutrophil degranulation, vasodilation and vascular permeability. Literature agrees on the beneficial effects of benzydamine in preventing and reducing oral mucositis severity in H&N cancer patients undergoing RT/CHT. CONCLUSIONS: Mucositis represents a major concern in H&N cancer patients and a clinical and economical issue. A multimodal and multidisciplinary approach is needed for its management. International guidelines recommend benzydamine for OM prevention and treatment in H&N cancer patients, but further “real world” trials should be designed.
format Online
Article
Text
id pubmed-8410701
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-84107012021-09-22 The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis Nicolatou-Galitis, Ourania Bossi, Paolo Orlandi, Ester René-Jean Bensadoun Support Care Cancer Original Article PURPOSE: To discuss the role of benzydamine in the prevention and treatment of radiation-induced oral mucositis (OM) in head and neck (H&N) cancer patients. This document represents an expert opinion paper on indications and key-role aspects in OM pathogenesis, prevention and treatment. ORAL MUCOSITIS: OM represents a common side effect of chemotherapy (CHT) and radiotherapy (RT). It consists in a painful erythema involving the oral cavity mucosa, which may progress to ulceration. Five biologically dynamic phases are considered crucial in mucositis: “initiation, signalling, amplification, ulceration and healing”. Oral environment and microbiota are fundamental in mucositis development being involved in susceptibility to infections and in ulceration consequences. Different agents against mucositis have been studied and the use of benzydamine is strongly supported in literature. The Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO) guidelines recommend its use for the prevention of OM in H&N patients undergoing RT and RT/CHT. BENZYDAMINE: Benzydamine is a local anti-inflammatory drug with analgesic properties. It can decrease TNF-α, IL-1β and prostaglandin synthesis, also inhibiting leukocyte-endothelial interactions, neutrophil degranulation, vasodilation and vascular permeability. Literature agrees on the beneficial effects of benzydamine in preventing and reducing oral mucositis severity in H&N cancer patients undergoing RT/CHT. CONCLUSIONS: Mucositis represents a major concern in H&N cancer patients and a clinical and economical issue. A multimodal and multidisciplinary approach is needed for its management. International guidelines recommend benzydamine for OM prevention and treatment in H&N cancer patients, but further “real world” trials should be designed. Springer Berlin Heidelberg 2021-03-01 2021 /pmc/articles/PMC8410701/ /pubmed/33649918 http://dx.doi.org/10.1007/s00520-021-06048-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Nicolatou-Galitis, Ourania
Bossi, Paolo
Orlandi, Ester
René-Jean Bensadoun
The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
title The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
title_full The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
title_fullStr The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
title_full_unstemmed The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
title_short The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
title_sort role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410701/
https://www.ncbi.nlm.nih.gov/pubmed/33649918
http://dx.doi.org/10.1007/s00520-021-06048-5
work_keys_str_mv AT nicolatougalitisourania theroleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis
AT bossipaolo theroleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis
AT orlandiester theroleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis
AT renejeanbensadoun theroleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis
AT nicolatougalitisourania roleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis
AT bossipaolo roleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis
AT orlandiester roleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis
AT renejeanbensadoun roleofbenzydamineinpreventionandtreatmentofchemoradiotherapyinducedmucositis